Scholarlink

Introduction <p>Due to several issues with endovascular treatment of intracranial symptomatic atherosclerotic disease (ICAD), international guidelines recommend drug therapy as first-line treatment since almost 10&#xa0;years. Regardless of this, endovascular ICAD treatment has meanwhile progressed, significantly reducing periprocedural complication rates.</p> <p>However, early in-stent restenosis (ISRS) remains, so far, unchallenged.</p> <p>Cardiologists had been at a similar point in the evolution of cardiac artery stenting and challenged ISRS through drug-eluting stents (DES).</p> <p>Therefore, 90d results and restenosis rates of patients treated with DES versus bare-metal stents (BMS) were compared to determine whether DES could also solve the neurovascular problem.</p> Methods <p>All endovascular ICAD treatments in 2014–2022 at a single institution through DES were retrospectively compared to all BMS-treatments in regards to periprocedural complications and ISR rates. Perioperative procedures and drug regimen were comparable for all patients, follow-up was carried out 90&#xa0;days after treatment through digital subtraction angiography, clinical status was recorded by a board certified neurologist.</p> Results <p>Fifty-two patients were treated for ICAD with DES, 26 patients received ICAD-treatment with BMS. Patients’ demographics and comorbidities were comparable. The periprocedural and ISR-rates were significantly lower in DES compared to BMS.</p> Discussion <p>The lower periprocedural complication rate may be due to less complexity of the DES system, while lower ISR in the DES group may be connected to reduced endothelium irritation and proliferation through the eluted sirolimus.</p> Conclusion <p>In the population studied, DES achieved equal to better results in comparison to BMS. This study supports a re-evaluation of the role of endovascular ICAD-treatment as first line therapy in the light of the most recent developments on knowledge and techniques.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug-eluting stents versus bare-metal stents in the treatment of drug-refractory intracranial atherosclerotic disease: a retrospective single-center comparison

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月26日

查看全文
  • Philipp von Gottberg,
  • Hans Henkes,
  • Kamran Hajiyev,
  • Michael Forsting,
  • Andrei Filioglo,
  • Hansjörg Bäzner,
  • Ali Khanafer

摘要

Introduction

Due to several issues with endovascular treatment of intracranial symptomatic atherosclerotic disease (ICAD), international guidelines recommend drug therapy as first-line treatment since almost 10 years. Regardless of this, endovascular ICAD treatment has meanwhile progressed, significantly reducing periprocedural complication rates.

However, early in-stent restenosis (ISRS) remains, so far, unchallenged.

Cardiologists had been at a similar point in the evolution of cardiac artery stenting and challenged ISRS through drug-eluting stents (DES).

Therefore, 90d results and restenosis rates of patients treated with DES versus bare-metal stents (BMS) were compared to determine whether DES could also solve the neurovascular problem.

Methods

All endovascular ICAD treatments in 2014–2022 at a single institution through DES were retrospectively compared to all BMS-treatments in regards to periprocedural complications and ISR rates. Perioperative procedures and drug regimen were comparable for all patients, follow-up was carried out 90 days after treatment through digital subtraction angiography, clinical status was recorded by a board certified neurologist.

Results

Fifty-two patients were treated for ICAD with DES, 26 patients received ICAD-treatment with BMS. Patients’ demographics and comorbidities were comparable. The periprocedural and ISR-rates were significantly lower in DES compared to BMS.

Discussion

The lower periprocedural complication rate may be due to less complexity of the DES system, while lower ISR in the DES group may be connected to reduced endothelium irritation and proliferation through the eluted sirolimus.

Conclusion

In the population studied, DES achieved equal to better results in comparison to BMS. This study supports a re-evaluation of the role of endovascular ICAD-treatment as first line therapy in the light of the most recent developments on knowledge and techniques.